Immunoblotting analysis of control versus TWEAK-treated TNBC, HER2 and ER-positive BC cell lines validated the similar levels of non-canonical NF-κB activation, without impacting canonical NF-κB, in all cell lines following TWEAK stimulation. The gene discussed is NFKB1; the disease is breast cancer.